EGFR and non-small cell lung carcinoma: Finally, NSCLC patients with EGFR mutations show poor response to anti-PD-1/PD-L1 treatment [159], and the mechanisms responsible for the lack of response to immunotherapy in such patients still remain unclear and need to be investigated.